Crown Bioscience Archives | Page 2 of 2

Home / Posts tagged Crown Bioscience (Page 2)

CrownBio Demonstrates Advantages of Innovative Translational Oncology Platform in Scientific Posters at AACR 2018 Meeting

SAN DIEGO, May 8 (Korea Bizwire) — Crown Bioscience, a wholly-owned subsidiary of Crown Bioscience International (TWSE:ticker 6554) and a global drug discovery and development services company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research, publishes scientific posters with dynamic audio narration. More than a dozen posters were presented at the [...]

CrownBio Launches New Humanized Target Model for Immunotherapy

SAN DIEGO, Apr. 26 (Korea Bizwire) — Crown Bioscience, a wholly-owned subsidiary of Crown Bioscience International (TWSE:6554) and a global drug discovery and development services company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research, enhances its existing portfolio of humanized drug target models (HuGEMM™) by launching a new transgenic CD3E model [...]

CrownBio to Showcase Scientific Expertise in Preclinical Drug Development at the American Association for Cancer Research (AACR) Conference

SAN DIEGO, Apr. 4 (Korea Bizwire) — Crown Bioscience, a wholly-owned subsidiary of Crown Bioscience International (TWSE:6554) and a global drug discovery and development services company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research, will showcase their scientific expertise at this year’s American Association for Cancer Research’s International Conference (AACR) in [...]

Glycotope Selects CrownBio as a Preclinical Development Partner to Advance Their Immunotherapeutic Pipeline

SAN DIEGO, Mar. 28 (Korea Bizwire) — Crown Bioscience, a wholly-owned subsidiary of Crown Bioscience International (TWSE:6554) and a global drug discovery and development services company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research, announces that it has been chosen by Glycotope GmbH as a partner to accelerate their immuno-oncology drug [...]

CBT Pharmaceuticals to Grow Immuno-Oncology Pipeline by License Agreement of CrownBio CTLA-4 Antibody

SAN DIEGO, Mar. 22 (Korea Bizwire) — Crown Bioscience, a wholly-owned subsidiary of Crown Bioscience International (TWSE:6554) and a global drug discovery and development services company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research, announced today a strategic licensing agreement with CBT Pharmaceuticals (CBT), a U.S. and China-based innovative biopharmaceutical company committed [...]